ECP in LBW GvHD Patients Medical Clinical Session

The Goal

The goal of the practical course is to provide expert information on important aspects that need to be considered when treating complex patients' conditions. The interactive setting fosters discussion between peers.

Agenda

Download Agenda PDF

Day 1 - 18 November 2026

13:00 – 13:20
Welcome coffee

13:20 – 13:30
Welcome and introduction - Dr. Hasan Hashem

13:30 – 13:45
The Pediatric BMT program at KHCC - Dr. Rawad Rihani

13:45 – 14:00
Potential Mechanism of THERAKOS ECP Immunomodulation™ - Mealis Medical Affairs

14:00 – 14:45
Acute GvHD - Dr. Hasan Hashem

• The role of ECP

• Patients’ selection

• Treatment schedule

• Response assessment

14:45 – 15:00
Acute GvHD - Dr. Rawad Rihani

• KHCC experience

15:00 – 16:00
Lunch

16:00 – 16:45
Chronic GvHD - Dr. Hasan Hashem

• The role of ECP

• Patients’ selection

• Organ involvement

• Treatment schedule

• Response assessment

16:45 – 17:00
Chronic GvHD - Dr. Rawad Rihani

• KHCC experience

17:00 – 17:15
Interactive discussion - All

20:00
Dinner with Faculty

Day 2 - 19 November 2026

09:00 – 10:00
Practical aspects for GvHD assessment - Dr. Hasan Hashem

10:00 – 11:00
Apheresis unit tour - All

11:00 – 11:15
Coffee break

11:15 – 13:00
Clinical cases presentation and discussions - All

13:00 – 13:15
Closing remarks - Dr. Hasan Hashem

13:15 – 14:15
Lunch

BMT: Bone Marrow Transplant, GvHD: Graft versus Host Disease, ECP: Extracorporeal Photopheresis, LBW: Low Body Weight

For this course, participants are required to submit one patient case for discussion 15 days in advance of the session

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd
This information is intended for healthcare professionals based in Europe and the Middle East.

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

Explore related courses

Oct 8 - 9, 2026

Educational Course on ECP Across GvHD, CTCL, HTx, LUTx Indications

Tribe Hotel, Budapest, Hungary

Find out more

Oct 21 - 22, 2026

Educational Course on the Management of GvHD

Wellcome Collection, London, United Kingdom

Find out more

Nov 26 - 27, 2026

Educational Course on Graft‑versus‑Host Disease: Evolving Landscape of GvHD Management

Novotel am Konzerthaus, Freiburg, Germany

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

ECP in LBW GvHD Patients Medical Clinical Session

The Goal

Agenda

Day 1 - 18 November 2026

Day 2 - 19 November 2026

Explore related courses

Educational Course on ECP Across GvHD, CTCL, HTx, LUTx Indications

Educational Course on the Management of GvHD

Educational Course on Graft‑versus‑Host Disease: Evolving Landscape of GvHD Management

Sign in to register your interest

Register your interest in attending